July 19, 2024
Biosimilars Market

Global Biosimilars Market is estimated to be valued at US$21.8 billion in 2022 and is expected to exhibit a CAGR of 15.9% over the forecast period of 2023-2030

Market Overview:

Biosimilars are alternative versions of biologic drugs that are highly similar to the reference products in terms of quality, safety, and efficacy. The increasing demand for cost-effective treatment options and the expiration of patents for several biologic drugs are driving the growth of the biosimilars market. Biosimilars offer significant cost savings compared to the reference products, making them an attractive choice for patients and healthcare providers.

Market Dynamics:

The biosimilars market is expected to witness significant growth during the forecast period due to various driving factors. Firstly, the increasing prevalence of chronic diseases, such as cancer, autoimmune disorders, and diabetes, is fueling the demand for biosimilars as they provide affordable treatment options. Secondly, the expiry of patents for several blockbuster biologic drugs is creating opportunities for biosimilar manufacturers to enter the market. Additionally, favorable government initiatives to promote the use of biosimilars and the growing acceptance of biosimilars among healthcare professionals are further boosting market growth. However, challenges related to the complex manufacturing process, stringent regulatory requirements, and the need for extensive clinical trials may hinder market growth to some extent. Overall, the biosimilars market is poised to experience robust growth in the coming years.

Market Key Trends:
The biosimilars market is expected to witness a significant growth rate of 15.9% during the forecast period from 2023 to 2030. This growth can be attributed to several factors including the increasing prevalence of chronic diseases such as cancer and autoimmune disorders, rising demand for cost-effective treatment options, and the expiration of patents for biologic drugs. Biosimilars offer similar efficacy and safety profiles as their reference biologic drugs, but at a lower cost, making them an attractive option for patients and healthcare providers. Additionally, government initiatives promoting the use of biosimilars and the entry of new players in the market are further driving the growth of the biosimilars market.

SWOT Analysis:
Strength: The biosimilars market offers cost-effective treatment options for patients, making it an attractive alternative to expensive biologic drugs. This affordability factor can drive market adoption.

Weakness: The complex manufacturing process of biosimilars and the need for comprehensive regulatory requirements pose challenges for market growth. Additionally, the lack of awareness among healthcare professionals and patients about biosimilars may hinder market expansion.

Opportunity: The expiration of patents for biologic drugs provides an opportunity for biosimilar manufacturers to enter the market. Additionally, the increasing prevalence of chronic diseases worldwide creates a growing demand for biosimilars.

Threats: Pricing pressures and intense competition from existing biologic drugs and other biosimilar manufacturers are potential threats to the biosimilars market. Furthermore, stringent regulatory policies and challenges in demonstrating the similarity and interchangeability of biosimilars with reference biologics may hinder market growth.

Key Takeaways:
The Global Biosimilars Market Size is expected to witness high growth, exhibiting a CAGR of 15.9% from 2023 to 2030, driven by the increasing prevalence of chronic diseases and rising demand for cost-effective treatment options.

North America is anticipated to be the fastest-growing and dominating region in the biosimilars market due to the presence of a well-established healthcare infrastructure and favorable government policies promoting the adoption of biosimilars. Europe is also expected to contribute significantly to market growth, driven by the increasing acceptance of biosimilars.

Key players operating in the biosimilars market include Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co., Ltd., Biocon Limited, Amgen, Inc., Dr. Reddy’s Laboratories, and Sanofi S.A. These players are focusing on strategic partnerships, acquisitions, and product launches to strengthen their market position and expand their biosimilars portfolio.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it